Characteristics of included trials
| Trial name* | Arm | N | Age | Male (%) | ECOG 1 (%) | Smoke (%) | ORR (%) | OS (months) | PFS (months) | DOR (months) | HR PFS (95% CI) | HR OS (95% CI) |
| ECOG4599, 2006 | TC +bevacizumab | 417 | 56.0 | 50.4 | 60.0 | NR | 35.0 | 12.3 | 6.2 | NR | 0.66 (0.57 to 0.77) | 0.79 (0.67 to 0.92) |
| TC | 433 | 58.0 | 58.4 | 60.0 | NR | 15.0 | 10.3 | 4.5 | NR | Ref | Ref | |
| JO19907, 2010 | TC +bevacizumab | 121 | 61.0 | 63.6 | 49.0 | 69.0 | 60.7 | 22.8 | 6.9 | 6.9 | 0.61 (0.42 to 0.89) | 0.99 (0.65 to 1.50) |
| TC | 59 | 60.0 | 64.4 | 51.0 | 68.0 | 31.0 | 23.4 | 5.9 | 5.6 | Ref | Ref | |
| AVAiL, 2010 | GP +bevacizumab | 351 | 59.0 | 62.4 | 59.0 | NR | 34.6 | 13.4 | 6.5 | 6.1 | 0.85 (0.73 to 1.00) | 1.03 (0.86 to 1.23) |
| GP | 347 | 59.0 | 64.3 | 59.0 | NR | 21.6 | 13.1 | 6.1 | 4.7 | Ref | Ref | |
| PRONOUNCE, 2015 | AC | 182 | 66.0 | 57.5 | 52.7 | 90.1 | 23.6 | 10.5 | 4.4 | NR | 1.06 (0.84 to 1.35) | 1.07 (0.83 to 1.36) |
| TC +bevacizumab | 179 | 65.0 | 58.1 | 53.1 | 96.1 | 27.4 | 11.7 | 5.5 | NR | Ref | Ref | |
| ERACLE, 2015 | AP | 60 | 60.0 | 70.0 | 22.0 | 70.0 | 40.0 | 14.0 | 8.1 | NR | 0.79 (0.53 to 1.17) | 0.93 (0.60 to 1.42) |
| TC +bevacizumab | 58 | 62.0 | 77.6 | 21.0 | 60.0 | 51.7 | 14.4 | 8.3 | NR | Ref | Ref | |
| BEYOND, 2015 | TC +bevacizumab | 138 | 57.0 | 54.3 | 75.0 | 50.0 | 54.0 | 24.3 | 9.2 | 8.0 | 0.40 (0.29 to 0.54) | 0.68 (0.50 to 0.93) |
| TC | 138 | 56.0 | 55.8 | 80.0 | 44.0 | 26.0 | 17.7 | 6.5 | 5.3 | Ref | Ref | |
| KEYNOTE-189, 2020 | AC/P+pembrolizumab | 410 | 65.0 | 62.0 | 53.9 | 88.3 | 48.0 | 22.0 | 9.0 | 11.2 | 0.48 (0.40 to 0.58) | 0.56 (0.45 to 0.70) |
| AC/P | 206 | 63.5 | 52.9 | 60.7 | 87.9 | 19.4 | 10.7 | 4.9 | 7.8 | Ref | Ref | |
| KEYNOTE-021, 2020 | AC+pembrolizumab | 60 | 62.5 | 37.0 | 58.0 | 75.0 | 58.0 | 34.5 | 24.5 | 36.3 | 0.54 (0.35 to 0.83) | 0.71 (0.45 to 1.12) |
| AC | 63 | 63.2 | 41.0 | 54.0 | 86.0 | 33.0 | 21.1 | 9.9 | 22.8 | Ref | Ref | |
| IMpower130, 2019 | Nab-TC +atezolizumab | 451 | 64.0 | 59.0 | 58.0 | 89.0 | 49.2 | 18.6 | 7.0 | 8.4 | 0.64 (0.54 to 0.77) | 0.79 (0.64 to 0.98) |
| Nab-TC | 228 | 65.0 | 59.0 | 60.0 | 92.0 | 31.9 | 13.9 | 5.5 | 6.1 | Ref | Ref | |
| IMpower132, 2020 | AC/p+atezolizumab | 292 | 64.0 | 65.8 | 56.8 | NR | 47.0 | 18.1 | 7.6 | 10.1 | 0.60 (0.49 to 0.72) | 0.81 (0.64 to 1.03) |
| AC/P | 286 | 63.0 | 67.1 | 59.9 | NR | 32.0 | 13.6 | 5.2 | 7.2 | Ref | Ref | |
| CheckMate 227, 2020 | AC/P+nivolumab | 270 | 63.0 | 36.0 | 61.0 | 82.0 | NR | 18.8 | 8.7 | NR | 0.67 (0.55 to 0.82) | 0.86 (0.69 to 1.08) |
| AC/P | 273 | 63.0 | 37.0 | 69.0 | 75.0 | NR | 15.5 | 5.8 | 6.2 | Ref | Ref | |
| CAMEL, 2019 | AC+camrelizumab | 205 | 59.0 | 71.2 | 76.6 | NR | 60.0 | NR | 11.3 | 17.6 | 0.60 (0.45 to 0.79) | 0.72 (0.52 to 1.01) |
| AC | 207 | 61.0 | 72.0 | 82.5 | NR | 39.1 | 20.9 | 8.3 | 9.9 | Ref | Ref | |
| RATIONALE 304, 2020 | AC/P+tislelizumab | 223 | 60.0 | 75.3 | 75.8 | 65.9 | 57.4 | NR | 9.7 | 8.5 | 0.65 (0.46 to 0.90) | NR |
| AC/P | 111 | 61.0 | 71.2 | 78.4 | 59.5 | 36.9 | NR | 7.6 | 6.0 | Ref | NR | |
| ORIENT 11, 2020 | AC/P+sintilimab | 266 | 61.0 | 76.7 | 71.4 | 64.3 | 51.9 | NR | 8.9 | NR | 0.48 (0.36 to 0.64) | 0.61 (0.40 to 0.93) |
| AC/P | 131 | 61.0 | 75.6 | 74.0 | 66.4 | 29.8 | NR | 5.0 | 5.5 | Ref | Ref |
*The references for the enrolled trials are listed in online supplemental additional table S1.
AC, pemetrexed +carboplatin; AC/P, pemetrexed +carboplatin/cisplatin; AP, pemetrexed +cisplatin; CI, confidence interval; DOR, duration of response; ECOG1, Eastern Cooperative Oncology Group 1; GP, gemcitabine +cisplatin; Nab-TC, nanoparticle albumin-bound paclitaxel +carboplatin; NR, not report; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; Ref, reference; TC, paclitaxel +carboplatin.